This dissected Jarvik-7 Total Artificial Heart (TAH), had been implanted in James Burcham April, 14, 1985 at the Humana Heart Institute International in Louisville, Kentucky. Burcham lived with the device for ten days. The heart pump has a right and left ventricle with four tilting disc valves. Each ventricle contains a flexible diaphragm constructed with multiple layers of polyurethane.
This is a demonstration model of the St. Jude Medical Masters aortic graft combined with a mechanical bi-valve artificial heart valve.
This type of device is implanted when both the natural valve and the aorta need to be reconstructed or replaced. It has an expandable cuff and wider sewing ring than 2005.0275.04. A disposable blue plastic implant tool is attached.
The ventricular assist device or the intrathoracic bypass pump as it was originally named was developed by a surgical research team led by Michael DeBakey (1908-2008), C. William Hall (1922-1992) and Domingo Liotta (1924- ) at Baylor University College of Medicine in Houston, Texas. The pneumatically powered pump is made of Silastic® and utilizes two ball-type valves to direct blood flow in one direction. It was the first bypass pump implanted in a human.
Heart assist devices or ventricular assist devices (VAD’s) are used to provide circulatory assistance to a weakened heart. The device helps pump blood through the aortic valve and into the aorta supplying blood to the rest of the body.
On July 18, 1963 this intrathoracic bypass pump was implanted into a 42 year old man who had undergone surgery to replace a diseased aortic valve. Hours later the patient suffered a cardiac arrest developing anuria (the decline of urine production) and fluid (edema) build up in his lungs. Although the pump help to relieve the edema the patients urine output never increased. The patient died four days after the pump was implanted.
Doctors considered the pump and other new mechanical devices such as the pacemaker and artificial heart valves successful, but they discovered that supplementing and indeed replacing the natural heart would not be easy. Among the problems which they encountered included damage to blood cells and the rejection of the device by the body. In the end physicians concluded, due to its long term support capabilities and the increase of blood circulation an internal artificial pump was feasible.
The N100PC is an implantable heart pump and drive system with a white outer cover and a precutanious lead. This device was first tested clinically in 1993, and remained in use until 2011. While researchers worked to develope a total artificial heart as a bridge to transplant several groups of scientists and engineers worked on smaller devices called Ventricular Assist Device or "VAD", a mechanical pump used to assist the blood output of the diseased heart. Unlike a total artificial heart, the patient’s natiral heart is left in place.
In select cases the VAD can be used as a long term recovery solution to chronic heart failure known as destination therapy. Groups working on both the artificial heart and VAD's encountered many of the same problems, particularly material compatibility to avoid blood clotting. In 1998, the Novacor LVAS was given FDA approval as a bridge to transplant.
This blood pump/drive unit is the original version of the Novacor Left Ventricular Assist (LVAS). It is the world's first clinically implanted electromechanical Ventricular Assist Device (VAD). While some researchers worked on developing a total artificial heart as a bridge to transplant several groups of scientists and engineers worked on developing the smaller heart assist device. In select cases the LVAD can be used as a long term recovery solution (destination therapy) to chronic heart failure. Groups working on both the artificial heart and VAD's encountered many of the same problems, particularly material compatibility to avoid blood clotting. In 1998, the Novacor LVAS was given FDA approval as a bridge to transplant.
A Ventricualr Assist Device (VAD) is a mechanical pump used to partially or completely replace a diseased human heart. Unlike a Total Artificial Heart, the patient’s human heart is left in place. The VAD assists the ventricles push blood through the body.
Introduced in 1992 the ATS is a bileaflet or open pivot heart valve. ATS Medical was founded in 1992 by Manny Villafaña, and acquired by Medtronic Inc. in April 2010. One of it's unique features is that it significantly lowers the sound levels caused when the occluder strikes the orifice as the valve closes. This became one of its selling points to doctors and patients. Many recipients of heart valves find the clicking noise of their prosthetic to be annoying and interfering with their sleep.
The Beall-Cromie is a caged-disc mitral valve coated with Teflon. it is similar in design to Charles Hufnagel's caged disk valve. In this model, the ring is large and the cage is flimsy. It was designed by Dr. Arthur Beall (1929-2002) of Baylor University College of Medicine and Harry Cromie, an engineer who was involved in designing the sutureless Magovern-Cromie valve. Beall worked with Dr. Michael DeBakey during his residency at Baylor.
Give-away items such as pens and paperwights are popular ways for companies to advertise their products. This plastic mechanical pen bears the Medtronic Inc. logo. It is white, blue, and black plastic with red print. It was used as a giveaway for advertising. There is a cap for the eraser end and the pencil works by twisting one end to expose the graphite. "MEDTRONIC INC. / 3055 Old Highway 8 / Minneapolis, Minn. 55418 U. S. A. / Phone (612) 781-6855"